Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid-guided chemotherapy in advanced thyroid cancer
NCT06713057Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, pemetrexed, fluorouracil, pegylated liposomal doxorubicin, vindesine and 5 more in Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective Response Rate at 12 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
cyclophosphamidepemetrexedfluorouracilpegylated liposomal doxorubicinvindesine
03
Conditions
Poorly differentiated thyroid cancer (PDTC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT06713057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713057.